190 related articles for article (PubMed ID: 19531926)
41. HIV-Related Lymphoproliferative Diseases in the Era of Combination Antiretroviral Therapy.
Castelli R; Schiavon R; Preti C; Ferraris L
Cardiovasc Hematol Disord Drug Targets; 2020; 20(3):175-180. PubMed ID: 32294049
[TBL] [Abstract][Full Text] [Related]
42. Antiretroviral treatment regimens and immune parameters in the prevention of systemic AIDS-related non-Hodgkin's lymphoma.
Stebbing J; Gazzard B; Mandalia S; Teague A; Waterston A; Marvin V; Nelson M; Bower M
J Clin Oncol; 2004 Jun; 22(11):2177-83. PubMed ID: 15169806
[TBL] [Abstract][Full Text] [Related]
43. The changing face of HIV-associated lymphoma: what can we learn about optimal therapy inl the post highly active antiretroviral therapy era?
Clayton A; Mughal T
Hematol Oncol; 2004 Sep; 22(3):111-20. PubMed ID: 15991221
[TBL] [Abstract][Full Text] [Related]
44. AIDS-related cancer and severity of immunosuppression in persons with AIDS.
Biggar RJ; Chaturvedi AK; Goedert JJ; Engels EA;
J Natl Cancer Inst; 2007 Jun; 99(12):962-72. PubMed ID: 17565153
[TBL] [Abstract][Full Text] [Related]
45. Non-Hodgkin lymphoma risk in adults living with HIV across five continents.
AIDS-defining Cancer Project Working Group of IeDEA, COHERE in EuroCoord
AIDS; 2018 Nov; 32(18):2777-2786. PubMed ID: 30234606
[TBL] [Abstract][Full Text] [Related]
46. High dose therapy and autologous stem cell transplantation for human immunodeficiency virus-associated non-Hodgkin lymphoma in the era of highly active antiretroviral therapy.
Molina A; Krishnan AY; Nademanee A; Zabner R; Sniecinski I; Zaia J; Forman SJ
Cancer; 2000 Aug; 89(3):680-9. PubMed ID: 10931469
[TBL] [Abstract][Full Text] [Related]
47. The International Prognostic Index can be used as a guide to treatment decisions regarding patients with human immunodeficiency virus-related systemic non-Hodgkin lymphoma.
Rossi G; Donisi A; Casari S; Re A; Cadeo G; Carosi G
Cancer; 1999 Dec; 86(11):2391-7. PubMed ID: 10590382
[TBL] [Abstract][Full Text] [Related]
48. Acquired immunodeficiency syndrome-related lymphoma in the era of highly active antiretroviral therapy.
Thirlwell C; Sarker D; Stebbing J; Bower M
Clin Lymphoma; 2003 Sep; 4(2):86-92. PubMed ID: 14556679
[TBL] [Abstract][Full Text] [Related]
49. Non-AIDS-defining deaths and immunodeficiency in the era of combination antiretroviral therapy.
Marin B; Thiébaut R; Bucher HC; Rondeau V; Costagliola D; Dorrucci M; Hamouda O; Prins M; Walker S; Porter K; Sabin C; Chêne G
AIDS; 2009 Aug; 23(13):1743-53. PubMed ID: 19571723
[TBL] [Abstract][Full Text] [Related]
50. Impact of highly active antiretroviral therapy in the treatment of HIV-infected patients with systemic non-Hodgkin's lymphoma.
Baiocchi OC; Colleoni GW; Navajas EV; Duarte LC; Alves AC; Andrade AL; Kerbauy J; Oliveira JS
Acta Oncol; 2002; 41(2):192-6. PubMed ID: 12102166
[TBL] [Abstract][Full Text] [Related]
51. Outcome in AIDS-related systemic non-Hodgkin lymphoma and leptomeningeal disease is not predicted by a CT brain scan.
Davies CL; Chinn R; Nelson M; Rasanesan M; Gazzard B; Powles T; Bower M; Stebbing J
AJNR Am J Neuroradiol; 2007; 28(10):1988-90. PubMed ID: 17898195
[TBL] [Abstract][Full Text] [Related]
52. Factors associated with the occurrence of AIDS-related non-Hodgkin lymphoma in the era of highly active antiretroviral therapy: Aquitaine Cohort, France.
Bonnet F; Balestre E; Thiébaut R; Morlat P; Pellegrin JL; Neau D; Dabis F;
Clin Infect Dis; 2006 Feb; 42(3):411-7. PubMed ID: 16392091
[TBL] [Abstract][Full Text] [Related]
53. Immunologic recovery in survivors following chemotherapy for AIDS-related non-Hodgkin lymphoma.
Bower M; Stebbing J; Tuthill M; Campbell V; Krell J; Holmes P; Ozzard A; Nelson M; Gazzard B; Powles T
Blood; 2008 Apr; 111(8):3986-90. PubMed ID: 18172004
[TBL] [Abstract][Full Text] [Related]
54. Human immunodeficiency virus-associated lymphomas in the antiretroviral therapy era: Analysis of the National Cancer Data Base.
Olszewski AJ; Fallah J; Castillo JJ
Cancer; 2016 Sep; 122(17):2689-97. PubMed ID: 27337679
[TBL] [Abstract][Full Text] [Related]
55. Impact of HIV Infection on the Clinical Presentation and Survival of Non-Hodgkin Lymphoma: A Prospective Observational Study From Botswana.
Milligan MG; Bigger E; Abramson JS; Sohani AR; Zola M; Kayembe MKA; Medhin H; Suneja G; Lockman S; Chabner BA; Dryden-Peterson SL
J Glob Oncol; 2018 Sep; 4():1-11. PubMed ID: 30241264
[TBL] [Abstract][Full Text] [Related]
56. Long-term survival of patients with HIV-related systemic non-Hodgkin's lymphomas.
Tirelli U; Errante D; Spina M; Vaccher E; Serraino D; Boiocchi M; Gloghini A; Carbone A
Hematol Oncol; 1996 Mar; 14(1):7-15. PubMed ID: 8613137
[TBL] [Abstract][Full Text] [Related]
57. [Non Hodgkin's and Hodgkin's lymphomas and HIV: frequency, outcome and immune response under HAART; Clermont-Ferrand University Hospital, 1991-2003].
Jacomet C; Lesens O; Villemagne B; Darcha C; Tournilhac O; Henquell C; Cormerais L; Gourdon F; Peigue-Lafeuille H; Travade P; Beytout J; Laurichesse H
Med Mal Infect; 2006 Mar; 36(3):157-62. PubMed ID: 16503104
[TBL] [Abstract][Full Text] [Related]
58. Influence of highly active anti-retroviral therapy on response to treatment and survival in patients with acquired immunodeficiency syndrome-related non-Hodgkin's lymphoma treated with cyclophosphamide, hydroxydoxorubicin, vincristine and prednisone.
Navarro JT; Ribera JM; Oriol A; Vaquero M; Romeu J; Batlle M; Flores A; Millá F; Feliu E
Br J Haematol; 2001 Mar; 112(4):909-15. PubMed ID: 11298585
[TBL] [Abstract][Full Text] [Related]
59. Prognosis of patients treated with cART from 36 months after initiation, according to current and previous CD4 cell count and plasma HIV-1 RNA measurements.
; Lanoy E; May M; Mocroft A; Phillip A; Justice A; Chêne G; Furrer H; Sterling T; Monforte AD; Force L; Gill J; Harris R; Hogg RS; Rockstroh J; Saag M; Khaykin P; de Wolf F; Sterne JA; Costagliola D
AIDS; 2009 Oct; 23(16):2199-208. PubMed ID: 19779320
[TBL] [Abstract][Full Text] [Related]
60. Epidemiology of non-Hodgkin lymphomas and other haemolymphopoietic neoplasms in people with AIDS.
Dal Maso L; Franceschi S
Lancet Oncol; 2003 Feb; 4(2):110-9. PubMed ID: 12573353
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
